News General

Next Generation IgM Immunoassays

March 22, 2021 - Spain

How Biokit is driving innovation in Immunoassays

Innovation is one of the strategic and fundamental Biokit pillars and we innovate at all levels, regarding biomaterials, assays, and manufacturing biotechnology processes. We aim to reinforce immunoassay know-how and technology capabilities, keeping in mind a final goal: increase efficiency and robustness, reduce time to market and streamline operations.

In Biokit, we enjoy, promote and benefit from a unique network of scientists, entrepreneurs and major players in the IVD sector allowing us to identify and incorporate the most innovative tools and technologies.

We work toward moving your immunoassay portfolio one-step beyond

Our innovation team worked towards the objective of developing a next-generation anti-toxoplasma IgM chemiluminescent immunoassay, with the following goals

  • To improve the performance and sensitivity of an existing commercial chemiluminescent immunoassay
  • To avoid animal use for antigen production
  • To increase robustness of calibrators & controls.

Our approach was to collaborate with academic institutions and innovative biotechnological companies to explore innovative solutions to address challenges and opportunities identified.

Next-gen igm immunoassays

By using an Anti-Toxoplasma IgM Chemiluminescent Immunoassay as a model, the approaches followed to reach the objectives were from one side innovate in the antigen used in the immunoassay and from the other side innovate in the sources for calibrators and controls. When looking to innovate in the antigen, specific IgM epitopes were identified through high throughput and multiplex technologies. Once the epitopes were identified, a multi-epitope synthetic peptide was synthetized and then coated in the magnetic particles of this next-generation IgM Chemiluminescent Immunoassay.

On the calibrators and controls side, the followed path was to use chimeric humanized IgM hybridomas as a source for calibrators and controls for this next generation IgM immunoassay.

Outcomes

The Next-generation Toxoplasma IgM Immunoassay was compared with a commercial Toxoplasma IgM and the obtained results were an increase of the sensitivity of 10% (up to 99%) and an increase of specificity of 4% (up to 97%).

In addition of reaching the objective of improving the sensitivity and specificity of an existing commercial Chemiluminescent Immunoassay, the objectives of avoiding animal requirement for antigen production and robust sources for calibrators & controls were also reached.

Find more details about this project in the Biokit Webinar Series: Next-Generation IgM Immunoassays.

Share Press Release:

LinkedIn twitter facebook

Contact us


Please contact us directly via telephone or with the following form.

Tel. +34 93 860 90 00

Data protection policy
Biokit, S.A. and Biokit Research & Development, S.L.U. will process your personal data to respond to your requests for information or support, or to understand your needs and provide you with a better service relying on our legitimate interest to do so. You can find more information about our data privacy practices and how to exercise your rights in our Privacy Policy (link). You can also contact us at DPO-biokit@werfen.com.